BACKGROUND: The feasibility and benefits of lifestyle intervention in chronic kidney disease (CKD) patients who are obese has not been well studied. We examined the early effects of an exercise plus weight loss intervention on body composition, exercise capacity, metabolic parameters and kidney function in obese subjects with CKD. METHODS: Nine subjects (median age 57 years, body mass index (BMI) 43.9) underwent a lifestyle intervention program that included supervised aerobic exercise (i.e. ∼85% maximum heart rate) and dietary counseling (500 kcal reduction in daily caloric intake). Body composition (iDXA), exercise capacity (maximal oxygen consumption), quality of life, insulin resistance (Matsuda index), inflammation (high sensitivity C-reactive protein), adipokines (leptin and total adiponectin) and kidney function (iothalamate glomerular filtration rate) were measured at baseline and after 12 weeks of the intervention. Changes in parameters were compared using the Wilcoxon signed-rank test. RESULTS: After 12 weeks of intervention, there was a significant decrease in BMI and fat mass (median -4.9 kg (25th-75th percentile -5.9 to -3.0)). There was a significant increase in exercise capacity (3.7 ml/kg/min (3.0-4.7)), along with improvements in insulin sensitivity (0.55 (0.43-1.2)), total adiponectin (780.9 μg/ml (262.1-1,497.1)) and leptin (-5.1 ng/ml (-14.5 to -3.3)). There were improvements in biomarkers of kidney disease very quality of life measures, but kidney function remained unchanged. CONCLUSION: Lifestyle modification is feasible in obese patients with CKD and produces weight loss that is related to improvements in exercise capacity, insulin resistance and adipokines. Whether lifestyle-induced weight loss and fitness can be sustained and whether it will mediate improvements in kidney function over time merits further investigation.
BACKGROUND: The feasibility and benefits of lifestyle intervention in chronic kidney disease (CKD) patients who are obese has not been well studied. We examined the early effects of an exercise plus weight loss intervention on body composition, exercise capacity, metabolic parameters and kidney function in obese subjects with CKD. METHODS: Nine subjects (median age 57 years, body mass index (BMI) 43.9) underwent a lifestyle intervention program that included supervised aerobic exercise (i.e. ∼85% maximum heart rate) and dietary counseling (500 kcal reduction in daily caloric intake). Body composition (iDXA), exercise capacity (maximal oxygen consumption), quality of life, insulin resistance (Matsuda index), inflammation (high sensitivity C-reactive protein), adipokines (leptin and total adiponectin) and kidney function (iothalamate glomerular filtration rate) were measured at baseline and after 12 weeks of the intervention. Changes in parameters were compared using the Wilcoxon signed-rank test. RESULTS: After 12 weeks of intervention, there was a significant decrease in BMI and fat mass (median -4.9 kg (25th-75th percentile -5.9 to -3.0)). There was a significant increase in exercise capacity (3.7 ml/kg/min (3.0-4.7)), along with improvements in insulin sensitivity (0.55 (0.43-1.2)), total adiponectin (780.9 μg/ml (262.1-1,497.1)) and leptin (-5.1 ng/ml (-14.5 to -3.3)). There were improvements in biomarkers of kidney disease very quality of life measures, but kidney function remained unchanged. CONCLUSION: Lifestyle modification is feasible in obesepatients with CKD and produces weight loss that is related to improvements in exercise capacity, insulin resistance and adipokines. Whether lifestyle-induced weight loss and fitness can be sustained and whether it will mediate improvements in kidney function over time merits further investigation.
Authors: Karen R Kelly; Sankar D Navaneethan; Thomas P J Solomon; Jacob M Haus; Marc Cook; Hope Barkoukis; John P Kirwan Journal: Med Sci Sports Exerc Date: 2014 Impact factor: 5.411
Authors: Sankar D Navaneethan; Jesse D Schold; John P Kirwan; Susana Arrigain; Stacey E Jolly; Emilio D Poggio; Srinivasan Beddhu; Joseph V Nally Journal: Clin J Am Soc Nephrol Date: 2013-02-14 Impact factor: 8.237
Authors: Thomas Pj Solomon; Jacob M Haus; Karen R Kelly; Marc D Cook; Julianne Filion; Michael Rocco; Sangeeta R Kashyap; Richard M Watanabe; Hope Barkoukis; John P Kirwan Journal: Am J Clin Nutr Date: 2010-10-27 Impact factor: 7.045
Authors: Hong Xu; Xiaoyan Huang; Johan Arnlöv; Tommy Cederholm; Peter Stenvinkel; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2014-01-16 Impact factor: 8.237
Authors: Lesley A Inker; Brad C Astor; Chester H Fox; Tamara Isakova; James P Lash; Carmen A Peralta; Manjula Kurella Tamura; Harold I Feldman Journal: Am J Kidney Dis Date: 2014-03-16 Impact factor: 8.860
Authors: S D Navaneethan; J P Kirwan; S Arrigain; M J Schreiber; A R Sehgal; J D Schold Journal: Int J Obes (Lond) Date: 2012-01-31 Impact factor: 5.095
Authors: Ciarán E Fealy; Stephan Nieuwoudt; Julie A Foucher; Amanda R Scelsi; Steven K Malin; Mangesh Pagadala; Lauren A Cruz; Miranda Li; Michael Rocco; Bartolome Burguera; John P Kirwan Journal: Exp Physiol Date: 2018-07 Impact factor: 2.969
Authors: Chaofan Li; Nengliang Yao; Stephanie L Miller; Christopher Macpherson; Taryn Hassinger; Kaitlin Love; Steven K Malin Journal: Int J Environ Res Public Health Date: 2022-05-29 Impact factor: 4.614
Authors: Steven K Malin; Sankar D Navaneethan; Ciaran E Fealy; Amanda Scelsi; Hazel Huang; Michael Rocco; John P Kirwan Journal: Obes Sci Pract Date: 2020-02-11